Redefining Care for BRCA and Other Familial-associated Cancers

Release Date: February 20, 2018
Expiration Date: February 20, 2019

Program Overview
Advances in molecular genetics and testing have refined the diagnosis, treatment, and follow-up for patients with BRCA and other familial genetic syndromes. As women with germline BRCA1 and BRCA2 mutations are at an increased risk for developing high-grade serous ovarian cancer, there are implications for genetic testing, family counseling, radiologic screening, and pharmaceutical choices in the community setting. Molecular and genetic advances, such as novel PARP inhibitors, are altering the treatment paradigm for recurrent ovarian cancer. Other familial cancer genetic syndromes are being rapidly identified and may have implications for screening, diagnosis, and treatment of those malignancies.

Appropriate evidence-based care and demonstration of high-quality care are consistent with clinical guidelines and will directly affect reimbursement incentives within the new payment models. This session will address these important new issues in cancer care.

Target Audience
The primary audiences for this activity are:

  • Community-based oncologists and hematologists; drivers of evidence-based practice changes, treatments, and care planning across multiple tumor types
  • Oncology nurses, advanced practice nurse (APNs), registered nurses (RNs), and nurse practitioners (NPs); primary point persons for patient management and education
  • Oncology, health-system, and managed-care pharmacists; responsible for dispensing cancer therapies, ensuring appropriate use, and including new agents on Formularies
  • Oncology treatment-team members involved in managing patients with cancer and providing supportive services (e.g. financial advocates, nutrition plans, psychological assessment, genetic counseling, and navigation)


 Jennifer Billiet, MGC, CGC
Genetic Counselor
 Greater Baltimore Medical Center
 Harvey Institute for Human Genetics
 Baltimore, MD



Jennifer Billiet, MGC, CGC is a Genetic Counselor in Cancer and Adult Genetics at the Harvey Institute for Human Genetics at Greater Baltimore Medical Center in Baltimore, MD.  She received a bachelor’s degree in biology from the University of Maryland, College Park, and a master’s degree in genetic counseling from University of Maryland, Baltimore.

She has previously worked in the University of Maryland Biochemical Genetics Laboratory and in the Cutaneous Nerve Laboratory at Johns Hopkins University. She is a member of the National Society of Genetic Counselors and is board-certified by the American Board of Genetic Counseling.

Educational Objectives
At the conclusion of this session, participants should be able to demonstrate the ability to:

  • Discuss current recommendations for genetic testing across multiple tumor types to facilitate management treatment selection
  • Review benefits and limitations of genetic testing as it continues to expand
  • Employ resources to increase patient access and engagement

Physician Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit TM.  Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Pharmacist Accreditation
The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

Pharmacist Designation
Total number of CE credits made available at this conference is 1.0 hours (0.10 CEUs).

UAN: 0418-9999-18-201-H04-P

A statement of credit will be issued only upon receipt of a completed activity evaluation.

This is an application-based activity.

For questions regarding CME/CE credit, the post-test, evaluation, please email

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Potomac Center for Medical Education, and Rockpointe Oncology.  Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Disclosure Information
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

Faculty Disclosures
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Jennifer Billiet, MGC, CGC: Nothing to disclose

Non-faculty Disclosures
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Chad Williamson, MS, MBA, CMPP; Shawna Graves, PhD; Blair St. Amand; Judi Smelker-Mitchek, RN, MSN, MBA; Trace Hutchinson, PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, MSN, FACEHP, RN, CHCP; Lindsay Scott, PT, DPT, ATC: Nothing to disclose

Gary I. Cohen, MD: Speaker’s Bureau: Genzyme, NantHealth; Shareholder: Celgene

Alex Ganetsky, PharmD: Honoraria/Advisory Board: Jazz; Speaker’s Bureau: Amgen, Incyte

FDA Disclosure
The content of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.

Instructions for Participants and Obtaining CME/CE Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/CE activity in its entirety, and then complete the post-test, with a score of 50% or better, and evaluation. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.  Participant is allowed to take the post-test multiple times.

Privacy Policy
Click here to view our privacy policy.


Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology


This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit